NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. Goodwill for the year ending December 31, 2023: USD 0.00

NewAmsterdam Pharma Company N.V. Goodwill is USD 0.00 for the year ending December 31, 2023, a -100.00% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

NewAmsterdam Pharma Company N.V. Goodwill for the year ending December 31, 2022 was USD 233.10 K, a 0.00% change year over year.
NewAmsterdam Pharma Company N.V. Goodwill for the year ending December 31, 2021 was USD 0.00.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Fintech Personal Care Pet Food Soft Drinks & Sodas Vaccines

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years